A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Prior treatment

• Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
• Clinically significant cardiac arrhythmias, high-grade AV block and third-degree AV block within 6 months prior to screening.
• Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 12 months prior to screening. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to screening.
  • Other protocol-defined inclusion/exclusion criteria may apply

Other illness

• Known history of secondary hypertension.
• Evidence of hepatic disease.
• Any history of congestive heart failure.
• Current or history of intolerance to ACEi and/or ARBs.

Lab values

• Laboratory parameter assessments outside of range at screening.

Other

• Orthostatic hypotension.

• Signed informed consent.
• Males or females aged 18 to 75 years.
• Diagnosis of hypertension.
• Hypertension treatment naive or on maximum 2 anti-HTN medications and able to undergo washout for 4 weeks.
• Mean sitting SBP ≥140 mmHg measured by OBPM and mean 24 hr SBP ≥130 mmHg and \<160 mmHg measured by ABPM.
• Participants able to understand and comply with study procedures.